ReShape Medical racks up $38 mln

San Clemente, California-based ReShape Medical, a weight loss-focused medical device company, has closed $38 million in Series D funding. HealthCor Partners Management LP led the round with participation from Endeavour Vision SA, SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners and Venture Investors.

Ximedica buys Bridge Design

Ximedica, an SV Life Sciences portfolio company, said Tuesday it has acquired Bridge Design. Financial terms weren’t announced. San Francisco-based Bridge Design provides design services for physical and digital products, including mHealth.

124 Views

Biotech company Avitide pulls in Series C funds

Lebanon, New Hampshire-based biotech company Avitide Inc has secured an undisclosed amount of Series C funding. NeoMed Management led the round with participation from previous backers Polaris Partners, OrbiMed Advisors, SV Life Sciences and Borealis Ventures. In addition to the funding, Claudio Nessi of NeoMed has been added to Avitide’s board of directors.

EBR Systems nets $20 mln

Sunnyvale, California-based EBR Systems Inc, a wireless cardiac pacing system provider for heart failure, has secured $20 million in funding. Emergent Medical Partners led the round with participation from other investors that include Split Rock Partners, SV Life Sciences, Delphi Ventures and St. Paul Venture Capital. According to the company, the capital infusion will be used for clinical studies and regulatory filings.

105 Views

VC-backed Entellus Medical sets IPO pricing terms

According to an amended SEC filing, Entellus Medical is planning on selling 4.375 million shares of its IPO at a price range between $15 and $17 per share. BofA Merrill Lynch and Piper Jaffray are serving as lead underwriters. Entellus will list the IPO on the NASDAQ under the ticker symbol “ENTL.” Based in Plymouth, Minnesota , Entellus Media provides treatment solutions for chronic sinusitis. Its backers include Covidien Ventures, SV Life Sciences, Essex Wodlands, Split Rock Partners and Greenspring Associates.

 

Merck acquires VC-backed OncoEthix

Merck has bought Swiss-based OncoEthix, a biotech firm that focuses on developing cancer drugs. The acquisition is being made with an upfront payment of up to $110 million. OncoEthix’s backers included Index Ventures, SV Life Sciences, Endeavour Vision and Edmond de Rothschild Investment Partners.

119 Views

CardioKinetix racks up $50 mln

CardioKinetix, a Menlo Park, Calif.-based medical device firm, has received $50 million in funding. Edwards Lifesciences Corp. led the round with participation from return backers U.S. Venture Partners, Tekla Healthcare Investors, Tekla Life Sciences Investors, SV Life Sciences, Panorama Capital, New Leaf Venture Partners and Lexington Private Equity. CardioKinetix has also inked an agreement with Edwards Lifesciences Corp. that gives the latter company the option to acquire CardioKinetix “based on future regulatory milestones.”

120 Views

SV Life Sciences backs Direct Flow Medical

Direct Flow Medical has raised $32 million in funding in a round led by SV Life Sciences. Also, the firm has hired Chris Richardson as its first chief commercial officer. Based in Santa Rosa, Calif., Direct Flow Medical is a provider of transcatheter technologies that treat heart disease.

176 Views

SV Life Sciences acquires majority stake in Ximedica

SV Life Sciences has bought a majority stake in Ximedica. No financial terms were disclosed. As a result of the transaction, Randall S. Barko, president and CEO of Ximedica and the company’s current management will remain. Also, Paul LaViolette, managing partner and COO at SV Life Sciences, has been named chairman of Ximedica’s board. Headquartered in Providence, RI, Ximedica is a medical tech firm.

166 Views

Bicycle Therapeutics reels in $32 mln

Bicycle Therapeutics has raised $32 million in funding. Previous backers Atlas Venture, Novartis Venture Fund, SR One, SV Life Sciences and Astellas Venture Management all participated in the round. Based in Cambridge, UK, Bicycle Therapeutics is a biotech firm focused on developing bicyclic peptides.

SV Life Sciences expands team with new hires

SV Life Sciences has hired Dan Burgess, Dr. Ed Mascioli and Dr. Michael Mendelsohn as new venture partners. Burgess was the founder, president and CEO of Rempex Pharmaceuticals while Mascioli was the CEO of Affinium Pharmaceuticals. And, previously, Mendelsohn worked at Merck Research Laboratories where he served as senior vice president and global franchise head, cardiovascular diseases.

PanOptica snags $45 mln Series B funds

PanOptica said Tuesday that it has closed up to $45 million in Series B funding. Novo Ventures and Third Rock Ventures led the round with participation from SV Life Sciences. Headquartered in Bernardsville, NJ, PanOptica is a biopharmaceutical firm focused on ophthalmology therapies.

141 Views

ICON agrees to acquire PE-backed Aptiv Solutions for $143.5 mln

ICON has agreed to buy Aptiv Solutions for a cash consideration of $143.5 million. The sellers are The Halifax Group, SV Life Sciences, Comvest Partners and Aptiv’s management. Headquartered in Reston, Virginia, Aptiv Solutions is a biopharmaceutical and medical device company.

Edmond de Rothschild Investment Partners Backs OncoEthix Series B

Edmond de Rothschild Investment Partners has backed the Series B financing round of OncoEthix through BioDiscovery 4, its fourth fund dedicated to life sciences. OncoEthix is a Swiss-based oncology drug development company founded in 2009. Edmond de Rothschild Investment Partners participated alongside SV Life Sciences and existing investors Index Ventures and Endeavour Vision.

Cibiem Appoints President and CEO

Medical device company Cibiem has appointed Ken Martin to president and chief executive officer. Martin will succeed Cibiem co-founder Howard R. Levin who will continue his active involvement within the company and as a member of its board of directors.The company is backed by SV Life Sciences and Third Rock Ventures.

SV Life Sciences Makes Black a Managing Partner

SV Life Sciences said Monday that Darren Black was named a managing partner while Tom Flynn was made a partner. Black joined SV Life Sciences in 2003 and will continue to focus on healthcare services, pharmaceutical services and healthcare information technology. Flynn joined the life sciences VC firm in 2011 and targets post-acute care delivery and healthcare information technology services.

PE HUB Community

Join the 12523 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget